CHRONIC BRONCHITIS · EMPHYSEMA · COPD GOLD STAGES II–IV
A physician-led, laboratory-verified treatment programme targeting the biological mechanisms behind airflow limitation, alveolar destruction and chronic airway inflammation — tailored to the individual phenotype, GOLD stage and clinical profile of each COPD patient.
Request Medical ConsultationAbout the Condition
Chronic Obstructive Pulmonary Disease (COPD) is a progressive respiratory condition characterised by persistent airflow limitation, chronic inflammation of the airways and destruction of alveolar tissue. The two principal pathological components — emphysema (destruction of air sacs) and chronic bronchitis (chronic mucus-producing inflammation of the bronchi) — frequently coexist in varying proportions.
As the disease advances, gas exchange deteriorates, exercise tolerance declines and exacerbations become more frequent. The resulting cycle of inflammation, tissue remodelling and loss of elastic recoil leads to progressive respiratory insufficiency that standard bronchodilator and corticosteroid therapy can manage symptomatically but cannot reverse.
COPD affects over 380 million people globally and remains the third leading cause of death worldwide. Current pharmacological management stabilises symptoms but does not address the underlying alveolar destruction or chronic inflammatory pathology — which is the focus of our cellular therapy programme.
Emphysema-predominant
Characterised primarily by destruction of the alveolar walls, leading to enlarged air spaces, reduced gas exchange surface area and loss of lung elastic recoil. Patients typically present with progressive breathlessness, hyperinflation and reduced diffusion capacity. Often associated with lower BMI and significant exercise limitation.
Chronic Bronchitis-predominant
Defined by chronic productive cough for at least three months in two consecutive years. Airway inflammation, goblet cell hyperplasia and excess mucus production are the dominant features. Patients are more prone to infectious exacerbations and airway obstruction from mucus plugging.
COPD-Asthma Overlap (ACO)
Patients exhibit features of both COPD and asthma — persistent airflow limitation combined with eosinophilic inflammation and partial bronchodilator reversibility. Represents approximately 15–20% of COPD diagnoses. Typically associated with earlier onset, more frequent exacerbations and distinct inflammatory profiles requiring adapted therapeutic strategy.
Frequent Exacerbator Phenotype
Defined by two or more moderate exacerbations or one hospitalisation per year. Exacerbations accelerate lung function decline, increase mortality risk and significantly impair quality of life. This phenotype persists independently of GOLD stage and requires targeted anti-inflammatory intervention beyond standard inhaler therapy.
Our program is individually adapted for all subtypes and all stages of progression.
Important: Each patient is accepted into the programme only after a comprehensive individual medical assessment, which evaluates diagnosis, GOLD stage, exacerbation history, pulmonary function tests and overall clinical profile.
We do not offer a cure for COPD. Our programme targets the biological mechanisms driving disease progression — with the clinical objective of reducing inflammation, supporting alveolar repair and improving functional respiratory capacity.
Clinical Outcomes
The following data are derived from structured observational analysis of patients treated at BioCells Medical between 2016 and 2025. All figures represent aggregated clinical registry outcomes with longitudinal follow-up. These are observational results — not randomised controlled trial data — and do not constitute a guarantee of therapeutic effect.
44
COPD patients treated since 2013
74%
measurable functional stabilisation on FEV1 at 3–6 months
+6.8%
average FEV1 score change at 6 months — vs. expected −2.5% natural decline
68%
sustained functional stability with average 2 years of follow-up
76%
showed improvement in one or more measured domains
72%
retained independence in basic activities of daily living (ADL) at 12 months
Respiratory function (FEV1 improvement, mMRC dyspnoea grade, supplemental oxygen need)
72%
Exercise tolerance (6MWT distance, walking endurance, daily activity capacity)
75%
Symptom control (exacerbation frequency and severity, sputum production, cough)
70%
Quality of life (daily energy, sleep, independence in ADL)
68%
2–6 weeks
Initial functional response
2–5 months
Clinically meaningful change
1–2 years onward
Long-term stability — continuous monitoring
Important: Outcomes depend on COPD phenotype, GOLD stage, baseline FEV1, exacerbation history, smoking status and individual biological response. Individual results may vary significantly.
Find out if our program can help in your specific case. The initial medical consultation is free and carries no obligation.
Request ConsultationPatient Stories
“I was on supplemental oxygen at home and could barely walk to the kitchen. After treatment I started getting through the mornings without reaching for the cannula. I can walk the dog again. For eight years everything went in one direction. Now it has shifted.”
Patient
COPD (emphysema-predominant, GOLD III) · United Kingdom
Every case is assessed individually by our physician team. Request a consultation to discuss your specific situation with our physician team.
Request ConsultationPatient Cases
Documented treatment outcomes recorded by the BioCells Medical team after personalised regenerative medicine protocols.
The BioCells Program
Our COPD programme combines five biological components into a single personalised protocol. No two protocols are identical — each is constructed following a detailed medical evaluation of the patient's respiratory profile, disease phenotype, inflammatory markers and clinical priorities.
Minimally invasive administration
Treatment is delivered by intravenous infusion or targeted local injection using specialised medical systems — not surgical instruments.
No general anaesthesia
Particularly important in COPD, where compromised respiratory function may make general anaesthesia high-risk.
No risk of immune rejection
MSCs are immunoprivileged: they express low levels of HLA-I, lack HLA-II and carry a minimal risk of rejection whether the protocol is autologous or allogeneic. Allogeneic MSC protocols do not require immunosuppression.
Targets the underlying biology, not just symptoms
Rather than managing airflow limitation with bronchodilators alone, our protocol targets alveolar destruction, chronic inflammation and immune dysregulation — the biological drivers of COPD progression.
Complements existing medication
Our programme is compatible with all standard COPD medications including inhaled corticosteroids, long-acting bronchodilators and phosphodiesterase inhibitors. Patients do not need to discontinue existing treatment.
Patients from around the world
We work with patients from around the world. Airport transfers, accommodation, visa support and multilingual coordination are included in every treatment programme.
What It Is
MSCs are multipotent regenerative cells with potent anti-inflammatory and tissue-repair properties. They have been extensively studied in respiratory disease and demonstrate capacity to modulate pulmonary inflammation while supporting alveolar tissue regeneration.
How It Is Done
Cells are collected from the patient's own bone marrow (autologous, approximately 3-5 ml under local anaesthesia) or sourced from a certified donor (allogeneic), depending on individual clinical indications. All cells are expanded, quality-controlled and tested in our certified Warsaw laboratory before administration.
Biological Mechanisms
How This Helps in COPD
In COPD, progressive destruction of alveolar walls reduces the gas exchange surface area and drives irreversible loss of lung elastic recoil. MSCs address this by delivering paracrine signals that support alveolar epithelial repair, suppress protease-mediated extracellular matrix degradation and create biological conditions that favour tissue stabilisation over continued parenchymal destruction.
Your Medical Board
The exact combination, dosage, sequencing and delivery method of all five components is determined individually by our medical board for each patient. No two treatment protocols are identical. Your programme is constructed based on your specific diagnosis, COPD phenotype, GOLD stage, biological markers and clinical priorities.
Your protocol is designed individually. Speak with our medical team to understand what your personalised program would include.
Request ConsultationPatient Journey
Your case is reviewed remotely by our physician team. We assess your diagnosis, current GOLD stage, pulmonary function data, exacerbation history and treatment goals. This consultation is free and carries no obligation.
A detailed review of all medical documentation including spirometry, CT imaging and blood work. Our medical board evaluates eligibility, confirms safety parameters and designs your personalised therapeutic protocol.
Your cells are collected, isolated, expanded and quality-tested in our certified Warsaw laboratory. Each batch receives a full traceability certificate. This stage typically takes 2–3 weeks.
Cells are delivered by intravenous infusion or targeted local administration — no surgery, no general anaesthesia. Airport transfers, accommodation and visa support are included in the programme for international patients.
Structured pulmonary rehabilitation sessions with our specialist, adapted to your current respiratory function and exercise capacity. Available at our clinic or remotely coordinated with your local respiratory team.
Your dedicated coordinator monitors respiratory status, exacerbation frequency, spirometry trends and overall well-being. A medical-grade wearable bracelet supports continuous health tracking regardless of your location.
The first step is free. Request a medical consultation and our medical consultant will contact you within 24 hours.
Request ConsultationSafety Profile
Cellular therapy is considered safe when delivered under proper medical supervision and according to validated protocols. In our practice, the procedure is well-tolerated by the majority of COPD patients.
Temporary mild reactions — such as transient local discomfort at the infusion site, slight fatigue or low-grade temperature — may occur in a minority of patients. These are typically short-lived and indicate active immune engagement.
A final medical assessment is performed on-site before every treatment session. If a patient's respiratory status has changed — including acute exacerbation or active infection — the programme may be temporarily modified or postponed for safety reasons.
All contraindications are evaluated individually. A contraindication in one clinical context does not necessarily preclude treatment in a different context — this is always determined by physician assessment.
Standard Contraindications
Active acute respiratory infection or pneumonia
Active malignancy or ongoing chemotherapy / radiotherapy
Acute COPD exacerbation requiring hospitalisation (treatment postponed until stable)
Severe decompensated cardiac or renal failure
Pregnancy
Post-Treatment
Dedicated pulmonary rehabilitation specialist
monitors respiratory function, exercise capacity and exacerbation patterns
Personalised home rehabilitation programme
breathing exercises, respiratory muscle training and graded activity protocols adapted to your current capacity
Medical-grade wearable monitoring
continuous oxygen saturation, heart rate and activity data supporting clinical decision-making
Long-term coordinator support
proactive check-ins, clinical guidance and response to any changes in respiratory status
Continued clinical access
our medical team remains available for ongoing reassessment, spirometry review and protocol adjustment
Pulmonary tissue repair follows a gradual biological timeline. The weeks and months following treatment are clinically critical — consistent rehabilitation, monitoring and medical follow-up directly influence long-term respiratory outcomes.
Get Started
If you or someone you care about has been diagnosed with COPD, our medical team is available for a free, no-obligation medical consultation — based on your diagnosis, current GOLD stage and individual clinical profile.
We review every inquiry personally. You will speak with a physician, not an administrator.
Submit your case online or by phone
Our medical consultant contacts you to review your documents
The medical board presents your personalised treatment plan
Request a Consultation
Tell us about your condition. Our medical consultant will contact you within 24 hours to review your documents.
Open Consultation FormMultilingual coordination — English, Italian, French, Russian, Polish
Evidence Base
Our clinical approach is informed by and consistent with published research in the field of regenerative medicine.
